Publication details

První zkušenosti s terapií Macugenem u vlhké formy VPMD

Title in English First experience with Macugen therapy in wet AMD
Authors

KOLÁŘ Petr

Year of publication 2007
MU Faculty or unit

Faculty of Medicine

Citation
Description Macugen (pegaptanib) is a modified oligonucleotide that specifically binds to the extracellular VEGF165, and inactivates it. Inhibits the processes of formation and progression of subretinal neovascularization. Selective inhibition of VEGF165 does not lead unlike non selective inhibition, to damage of the physiological vascular structure of the choroid.

You are running an old browser version. We recommend updating your browser to its latest version.

More info